It will be effective to enter first generic business in the U.S. making use of strategy to avoid invalidity of patent or evasion of patent
Team manager of Boryung Pharmaceutical patent team Kim Kwang-Bum, wrote for a 'KPMA Brief' first issue (the May issue) which is released from Korean Pharmaceutical Manufacturers Association with the topic of 'Overview for the possibility of entering into U.S. generic drug market and Drug Approval...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
